The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.
 
Amer Methqal Zeidan
Honoraria - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Consulting or Advisory Role - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; Astex Pharmaceuticals; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Research Funding - Abbvie (Inst); Amgen; Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Geron; Kura Oncology; Novartis (Inst); Otsuka; Shattuck Labs; Syros Pharmaceuticals; Takeda (Inst)
 
Valeria Santini
Honoraria - Celgene/Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Abbvie; Celgene/Bristol-Myers Squibb; CTI; Curis; Geron; Gilead Sciences; Novartis; Otsuka; SERVIER; Syros Pharmaceuticals
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag
 
Uwe Platzbecker
Honoraria - Abbvie; Celgene/Jazz; Curis; Geron; Janssen
Consulting or Advisory Role - BMS GmbH & Co. KG; Celgene/Jazz; Novartis
Research Funding - Amgen (Inst); BerGenBio (Inst); Celgene (Inst); Curis (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - part of a patent for a TFR-2 antibody (Rauner et al. Nature Metabolics 2019)
Travel, Accommodations, Expenses - Celgene
 
Mikkael A. Sekeres
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Kurome Therapeutics; Novartis; Syros Pharmaceuticals
Research Funding - Bristol-Myers Squibb (Inst); Rigel (Inst); Takeda (Inst)
 
Michael R. Savona
Stock and Other Ownership Interests - Karyopharm Therapeutics; Ryvu Therapeutics
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Forma Therapeutics; Geron; Karyopharm Therapeutics; Novartis; Ryvu Therapeutics; Sierra Oncology; Taiho Oncology; Takeda; TG Therapeutics
Research Funding - ALX Oncology (Inst); Astex Pharmaceuticals (Inst); Incyte (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Pierre Fenaux
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Yazan Madanat
Honoraria - Blueprint Medicines; Bristol Myers Squibb; GERON; Kura Oncology; MorphoSys; Novartis; OncLive/MJH Life Sciences; Rigel; Sierra Oncology; SOBI; Stemline Therapeutics; Taiho Oncology
Consulting or Advisory Role - Geron
Travel, Accommodations, Expenses - Blueprint Medicines; MorphoSys
 
Azra Raza
Leadership - GRAIL; TFC Therapeutics
Stock and Other Ownership Interests - TFC Therapeutics
Honoraria - Epizyme; Taiho Oncology
Consulting or Advisory Role - Genzyme; Janssen; Takeda; TFC Therapeutics
Research Funding - GRAIL; Immuneel Therapeutics; Rarecells; Regeneron
Patents, Royalties, Other Intellectual Property - Alercell; TFC Therapeutics
Travel, Accommodations, Expenses - GRAIL; Rarecells
 
Qi Xia
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Libo Sun
Employment - Geron; Novartis (I)
Stock and Other Ownership Interests - Geron; Johnson & Johnson; Novartis (I)
Travel, Accommodations, Expenses - Geron
 
Jennifer Riggs
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Sheetal Shah
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Shyamala Chendeal Navada
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Tymara Berry
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Rami S. Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; CTI BioPharma Corp; DSI; Geron; Gilead/Forty Seven; Jazz Pharmaceuticals; Novartis; Pharmaessentia; Sumitomo Pharma Oncology; Taiho Oncology; Takeda
Speakers' Bureau - Abbvie; CTI BioPharma Corp; Jazz Pharmaceuticals; Pharmaessentia; SERVIER
Research Funding - Bristol-Myers Squibb/Celgene (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Jazz Pharmaceuticals; Pharmaessentia